Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML

This study is testing whether a lower dose of radotinib — a drug that blocks the abnormal protein driving chronic myeloid leukemia (CML) — can work just as well as the standard dose while causing fewer side effects in patients newly diagnosed with chronic phase CML that has the Philadelphia chromosome (a specific genetic abnormality). **You may be eligible if...** - You are 19 or older - You have been newly diagnosed with chronic phase CML within the past 8 weeks - Your diagnosis has been confirmed by chromosome or bone marrow testing - You have the Philadelphia chromosome (BCR-ABL1 gene change) confirmed - Your organ function (liver, kidneys) meets acceptable levels - You are generally healthy enough to participate (ECOG score 0-2) **You may NOT be eligible if...** - Your CML is in an accelerated or blast phase (more advanced stage) - You have already started treatment for CML - You have serious liver, kidney, or pancreatic problems - You are pregnant, breastfeeding, or unwilling to use contraception Talk to your doctor to see if this trial is right for you.